Tirzepatide Improves HRQoL Compared to Insulin Lispro in Poorly Controlled Basal Insulin-treated Adults with Long-standing T2D (SURPASS-6)

Does tirzepatide (TZP) improve HRQoL compared to insulin lispro (iLispro) in adults with type 2 diabetes (T2D) treated with basal insulin?

Methods: In SURPASS-6, adults with T2D and inadequate glycemic control were randomized (1:1:1:3) to TZP 5, 10, or 15 mg QW, or iLispro TID, as add-on to optimized insulin glargine, with or without metformin, for 52 weeks in this open-label, multicenter, Phase 3b study. HRQoL was measured at baseline and endpoint (Week 52) using the SF-36v2 acute form comprised of 8 domains and 2 component summary scores.

Results: Overall, 1428 participants with mean baseline age 59 y, T2D duration 14 y, HbA1c 8.8% and BMI 33.1 kg/m2 were randomized. At endpoint, TZP-treated participants had statistically significantly improved scores across all SF-36v2 domains and component summaries compared to iLispro-treated participants, with the largest differences observed in the General health (LS mean [SE] change 3.0 [0.31] vs. -0.1 [0.32]) and Vitality (1.5 [0.31] vs. -1.1 [0.32]) domains.

Conclusion: TZP treatment resulted in greater improvements across multiple domains of HRQoL than iLispro in adults with long standing T2D already treated with basal insulin.

 

Scroll to top

Interessenkonflikt

Study was funded by Eli Lilly and Company. Kristina Boye, Helene Sapin, Jiat Ling Poon, Laura Fernández Landó, Ruth Huh, and Hiren Patel are full-time employees and minor stock-holders of Eli Lilly and Company. Mianbo Wang works as a consultant for Eli Lilly and Company.

Publication History

Article published online:
18 April 2024